Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Biogen Inc.NASDAQ: BIIB
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin narrows to 11.6%
Operating margin was 11.6% in Q2 FY2026, down 10.6 pp from a year earlier. On a trailing-twelve-month basis it was 12.8%, down 11.3 pp year over year. Over 3 fiscal years it narrowed by 9.3 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 26 analysts of 22.3% for the fiscal year ending Dec 2026, up from 19.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 11.6%-4.4 pp QoQ
- Last fiscal yearDec 2025
- 19.1%-6.6 pp YoY
- LTMJun 2026
- 12.8%-11.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.6 pp | -9.0 pp | +1.6 pp |
| 1 year | -6.6 pp | +3.2 pp | +9.8 pp |
| 3 years | -9.3 pp | +10.8 pp | +20.1 pp |
| 5 years | +12.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 19.1%
- Year-over-year change
- -6.6pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.1% | -6.6pp |
| FY2024 | 2024-12-31 | 25.7% | +4.4pp |
| FY2023 | 2023-12-31 | 21.3% | -7.1pp |
| FY2022 | 2022-12-31 | 28.4% | +3.0pp |
| FY2021 | 2021-12-31 | 25.4% | — |
Operating Margin vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 operating margin of 12.8% is the 9th highest of the 11 companies compared; the peer median is 26.1%.
- Its year-over-year change of -11.3 pp is the 9th highest of 11, against a peer median of +0.2 pp.
- Over three fiscal years its change of -9.3 pp compares with a peer median of +6.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 49.7% | +7.6 pp | +15.2 pp | |
| LTM Jun 2026 | 44.5% | -2.6 pp | -2.9 pp | |
| LTM Sep 2026 | 33.9% | -0.2 pp | -8.8 pp | |
| LTM Jun 2026 | 33.2% | +9.7 pp | -7.3 pp | |
| LTM Jun 2026 | 26.7% | +0.6 pp | -9.9 pp | |
| LTM Jun 2026 | 25.6% | -1.5 pp | -19.3 pp | |
| LTM Sep 2026 | 23.7% | +1.6 pp | +14.9 pp | |
| LTM Jun 2026 | 20.8% | +28.1 pp | +89.2 pp | |
| LTM Jun 2026 | 12.8% | -11.3 pp | -9.3 pp | |
| LTM Jun 2026 | 11.5% | -29.2 pp | +113.5 pp | |
| LTM Sep 2026 | -58.9% | -30.2 pp | +29.4 pp | |
| Peer median (excluding BIIB) | 26.1% | +0.2 pp | +6.0 pp | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.98B | 10.17B | 9.84B | 9.68B | 9.81B |
| Cost of Revenue | 2.11B | 2.28B | 2.53B | 2.31B | 2.9B |
| Gross Profit | 8.87B | 7.9B | 7.3B | 7.37B | 6.91B |
| Gross Margin | 80.8% | 77.6% | 74.2% | 76.1% | 70.5% |
| Research & Development | 3.4B | 2.6B | 2.7B | 2.49B | 1.95B |
| Selling, General & Admin | 2.68B | 2.41B | 2.5B | 2.39B | 2.43B |
| Operating Expenses | 6.08B | 5.01B | 5.2B | 4.88B | 5.04B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| EBITDA | 3.92B | 3.54B | 2.38B | 3B | 2.95B |
| EBITDA Margin | 35.7% | 34.8% | 24.2% | 31.0% | 30.0% |
| Operating Income | 2.79B | 2.89B | 2.1B | 2.49B | 1.88B |
| Operating Margin | 25.4% | 28.4% | 21.3% | 25.7% | 19.1% |
| Interest Income | 11M | 89.3M | 276.5M | 67.6M | 87.8M |
| Interest Expense | 253.6M | 246.6M | 246.9M | 250.3M | 246M |
| Other Income / Expenses | (1.01B) | 705.3M | (800.5M) | (584.3M) | (476M) |
| Income Before Tax | 1.78B | 3.59B | 1.3B | 1.91B | 1.4B |
| Pre-Tax Margin | 16.2% | 35.3% | 13.2% | 19.7% | 14.3% |
| Income Tax Expense | 52.5M | 632.8M | 135.3M | 273.8M | 108.11M |
| Net Income | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B |
| Net Margin | 14.2% | 29.9% | 11.8% | 16.9% | 13.2% |
| EPS (Basic) | 10.44 | 20.97 | 8.02 | 11.20 | 8.85 |
| EPS (Diluted) | 10.40 | 20.87 | 7.97 | 11.19 | 8.83 |
| Weighted Avg Shares | 149.1M | 145.3M | 144.7M | 145.7M | 146.7M |
| Weighted Avg Shares (Diluted) | 149.6M | 146M | 145.6M | 145.9M | 146.7M |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.